Revvity Inc.
RVTY | NYSE
$157.00
-$8.78 (-5.30%)
At close: Oct 30, 2026, 4:00 PM ET
$157.00
$0.00 (0.00%)
Pre-market:
Nov 2, 2026, 8:24 AM ET
Company Profile
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
Key Executives
| Name | Position |
|---|---|
| Prahlad R. Singh | Chief Executive Officer, President & Director |
| Maxwell Krakowiak | Senior Vice President & Chief Financial Officer |
| Anita Gonzales | Chief Accounting Officer, Vice President & Controller |
| Bryan A. Kipp | Senior Vice President of Technology & Licensing |
| Joel S. Goldberg | Senior Vice President of Administration, General Counsel & Secretary |
| Madhuri FACMG | Senior Vice President & Chief Scientific Officer |
| Magali Four | Senior Vice President & Chief People and Culture Officer |
| Miriame Victor | Senior Vice President & Chief Business Officer |
| Stephen Barr Willoughby | Senior Vice President of Investor Relations & Head of ESG |
| Tajinder Vohra | Senior Vice President of Global Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 02, 2026 | 4 | Filing |
| Sep 23, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 08, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 25, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 17, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 11, 2026 | 10-Q | Quarterly Report |
Revvity Inc.
| Country | United States |
| IPO Date | Jul 6, 1965 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 11,000 |
| CEO | Prahlad R. Singh |
Contact Details
77 4th Avenue Waltham,
Massachusetts 02451 United States
Stock Details
| Ticker Symbol | RVTY |
| Exchange | NYSE |
| Fiscal Year | February - January |
| Reporting Currency | USD |
| CIK Code | 0000031791 |
| CUSIP Number | 714046109 |
| ISIN Number | US7140461093 |
| SIC Code | 3826 |
Recent News
- 2 days ago / businesswire.comRevvity Board Declares Quarterly Dividend
- 3 days ago / zacks.comRevvity Gears Up to Post Q3 Earnings: What's in Store for the Stock?
- 6 days ago / zacks.comWill Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report?
- 6 days ago / zacks.comRevvity (RVTY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- 10 days ago / zacks.comELV vs. RVTY: Which Stock Is the Better Value Option?
- 11 days ago / zacks.comRevvity Launches Signals LabGistics to Coordinate Scientific Workflows
- 11 days ago / seekingalpha.comRevvity: A Diagnostics Annuity Is Quietly Funding An AI Data Engine
- 20 days ago / businesswire.comRevvity to Present at Upcoming Investor Conferences
- 27 days ago / businesswire.comRevvity to Host Investor Day
- 1 month ago / zacks.comRevvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock?
Add to Watchlist
Select watchlists to add or remove RVTY